The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | NIVO + chemo vs chemo as 1L treatment for advanced GC/GEJC/EAC: 4 year yr follow-up of CheckMate 649
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, presents the 4-year follow-up results of the Phase III CheckMate 649 (NCT02872116) trial, evaluating nivolumab in combination with chemotherapy (chemo) versus chemo alone in previously untreated, advanced non-HER2+ gastric cancer/gastroesophageal junction/esophageal adenocarcinoma (GC/GEJC/EAC). The study, which demonstrated superior overall survival (OS) and progression-free survival (PFS) benefits with nivolumab + chemo, continues to show efficacy in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥ 5. nivolumab + chemo maintains a favorable safety profile, making it the first PD-1 inhibitor/chemo combination to exhibit long-term efficacy and safety after 4 years in this patient population. This interview occurred at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
